Stomach neoplasms,Drug therapy,Combination,Medicine, Chinese traditional,Integrative medicine,Plants, medicinal ," /> Stomach neoplasms,Drug therapy,Combination,Medicine, Chinese traditional,Integrative medicine,Plants, medicinal ,"/> Traditional Chinese medicine integrated with chemotherapy for stage IV non-surgical gastric cancer: A retrospective clinical analysis
Search JIM Advanced Search

Journal of Integrative Medicine ›› 2017, Vol. 15 ›› Issue (6): 469-475.doi: 10.1016/S2095-4964(17)60377-7

Special Issue: Traditional Chinese Medicine

• Research Article • Previous Articles     Next Articles

Traditional Chinese medicine integrated with chemotherapy for stage IV non-surgical gastric cancer: A retrospective clinical analysis

Xuan Liu, Li-juan Xiu, Jian-peng Jiao, Jing Zhao, Ying Zhao, Ye Lu, Jun Shi, Yong-jin Li, Min Ye, Yu-fang Gu, Xiao-wei Wang, Jing-yu Xu, Ci-an Zhang, Yong-ying Liu, Yun Luo, Xiao-qiang Yue   

  1. Department of Traditional Chinese Medicine, Changzheng Hospital, Second Military Medical University, Shanghai 200003, China
  • Received:2017-03-20 Accepted:2017-08-14 Online:2017-11-15 Published:2017-11-07
  • Contact: Xiao-qiang Yue, PhD, Associate Professor; E-mail:
  • Supported by:
    This study was financially supported by the Natural Science Foundation of Shanghai Science and Technology Commission (No. 17ZR1438800, for Dr. Xuan Liu), Traditional Chinese Medicine Guiding Project of Shanghai Science and Technology Commission (No.13401907500, for Zhi-feng Qin), Shanghai Municipal Commission of Health and Family Planning Program (No. ZY3-CCCX-3-3056, for Dr. Li-juan Xiu) and National Natural Science Foundation Youth Program (No. 81603434, for Dr. Li-juan Xiu).


Traditional Chinese medicine (TCM) is regarded as an important treatment for gastric cancer patients, especially for those in advanced stage. To evaluate the effects of TCM treatment on gastric cancer patients, the authors performed a retrospective study to report the result of the integrated treatment of TCM with chemotherapy for stage IV non-surgical gastric cancer.


In this study, 182 patients with stage IV and non-surgical gastric cancer were retrospectively analyzed to evaluate the effects of TCM integrated with chemotherapy. Among the 182 cases, 88 cases received integrated therapy consisting of TCM and chemotherapy, while 94 cases received chemotherapy alone. The overall survival and Karnofsky performance status (KPS) score were measured as the main outcome.


The median overall survival of the integrated therapy group and chemotherapy group were 16.9 and 10.5 months, respectively. The 1-, 3- and 5-year survival rates of integrated therapy group vs. chemotherapy group were 70% vs. 32%, 18% vs. 4%, and 11% vs. 0%, respectively. There was a significant difference between the two groups (χ2 = 42.244, P < 0.001). After six-month treatment, KPS scores of the integrated therapy group and the chemotherapy group were 75.00 ± 14.78 and 60.64 ± 21.39, respectively (P < 0.001). The Cox regression analysis showed that TCM treatment is a protective factor for patients' overall survival.


This study demonstrated that TCM integrated with chemotherapy may prolong overall survival and improve survival rate and life quality of patients with stage IV non-surgical gastric cancer.

Key words: Stomach neoplasms, Drug therapy, Combination, Medicine, Chinese traditional, Integrative medicine, Plants, medicinal

1 de Martel C, Forman D, Plummer M. Gastric cancer: epidemiology and risk factors.Gastroenterol Clin North Am. 2013; 42(2): 219-240.
2 Yang D, Hendifar A, Lenz C, Togawa K, Lenz F, Lurje G, Pohl A, Winder T, Ning Y, Groshen S, Lenz HJ.Survival of metastatic gastric cancer: significance of age, sex and race/ ethnicity.J Gastrointest Oncol. 2011; 2(2): 77-84.
3 Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015; 136(5): E359-E386.
4 Liu N, Wang X. Current status and research progress of perioperative chemotherapy in advanced gastric cancer. Zhonghua Wei Chang Wai Ke Za Zhi.2015; 18(10): 983- 985. Chinese with abstract in English.
5 Moehler M, Mueller A, Trarbach T, Lordick F, Seufferlein T, Kubicka S, Geissler M, Schwarz S, Galle PR, Kanzler S; German Arbeitsgemeinschaft Internistische Onkologie. Cetuximab with irinotecan, folinic acid and 5-fluorouracil as first-line treatment in advanced gastroesophageal cancer: a prospective multi-center biomarker-oriented phase II study.Ann Oncol. 2011; 22(6): 1358-1366.
6 Davies AR, Gossage JA, Zylstra J, Mattsson F, Lagergren J, Maisey N, Smyth EC, Cunningham D, Allum WH, Mason RC.Tumor stage after neoadjuvant chemotherapy determines survival after surgery for adenocarcinoma of the esophagus and esophagogastric junction. J Clin Oncol.2014; 32(27): 2983-2990.
7 Iveson T, Donehower RC, Davidenko I, Tjulandin S, Deptala A, Harrison M, Nirni S, Lakshmaiah K, Thomas A, Jiang Y, Zhu M, Tang R, Anderson A, Dubey S, Oliner KS, Loh E.Rilotumumab in combination with epirubidin, cisplatin, and capecitabine as first-line treatment for gastric or oesophagogastric junction adenocarcinoma: an openlabel, dose-de-escalation phase 1b study and a double-blind, randomised phase 2 study.Lancet Oncol. 2014; 15(9): 1007-1018.
8 Pinto C, Di Fabio F, Barone C, Siena S, Falcone A, Cascinu S, Rojas Llimpe FL, Stella G, Schinzari G, Artale S, Mutri V, Giaquinta S, Giannetta L, Bardelli A, Martoni AA.Phase II study of cetuximab in combination with cisplatin and docetaxel in patients with untreated advanced gastric or gastro-oesophageal junction adenocarcinoma (DOCETUX study). Br J Cancer.2009; 101(8): 1261-1268.
9 Sun DZ, Liu L, Jiao JP, Wei PK, Jiang LD, Xu L. Sydrome characteristics of traditional Chinese medicine: summary of a clinical survey in 767 patients with gastric cancer. Zhong Xi Yi Jie He Xue Bao.2010; 8(4): 321-330. Chinese with abstract in English.
10 Ji Q, Luo YQ, Wang WH, Liu X, Li Q, Su SB.Research advances in traditional Chinese medicine sydromes in cancer patients.J Integr Med. 2016; 14(1): 12-21.
11 Wu AW, Ji JF.Neoadjuvant chemotherapy for locally advanced gastric cancer: with or without radiation.World J Gastrointest Surg. 2012; 4(2): 27-31.
12 Zhang LP, Liao XY, Xu YM, Yan LJ, Yan GF, Wang XX, Duan YZ, Sun JG.Efficacy and safety of endostar® combined with chemotherapy in patients with advanced soft tissue sarcomas.Asian Pac J Cancer Prev. 2013; 14(7): 4255-4259.
13 Casaretto L, Sousa PL, Mari JJ.Chemotherapy versus support cancer treatment in advanced gastric cancer: a metaanalysis.Braz J Med Biol Res. 2006; 39(4): 431-440.
14 Yonemura Y, Elnemr A, Endou Y, Ishibashi H, Mizumoto A, Miura M, Li Y.Effects of neoadjuvant intraperitoneal/ systemic chemotherapy (bidirectional chemotherapy) for the treatment of patients with peritoneal metastasis from gastric cancer.Int J Surg Oncol. 2012; 2012: 148420.
15 Kitayama J, Ishigami H, Yamaguchi H, Yamashita H, Emoto S, Kaisaki S, Watanabe T.Salvage gastrectomy after intravenous and intraperitoneal paclitaxel (PTX) administration with oral S-1 for peritoneal dissemination of advanced gastric cancer with malignant ascites.Ann Surg Oncol. 2014; 21(2): 539-546.
16 Rivera F, Vega-Vi l l e g a s ME, López-Brea MF. Chemotherapy of advanced gastric cancer.Cancer Treat Rev. 2007; 33(4): 315-324.
17 Ling CQ, Yue XQ, Ling C.Three advantages of using traditional Chinese medicine to prevent and treat tumor.J Integr Med. 2014; 12(4): 331-335.
18 Rosati G, Ferrara D, Manzione L.New perspectives in the treatment of advanced or metastatic gastric cancer.World J Gastroenterol. 2009; 15(22): 2689-2692.
19 Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, Lordick F, Ohtsu A, Omuro Y, Satoh T, Aprile G, Kulikov E, Hill J, Lehle M, Rüschoff J, Kang YK; ToGA Trial Investigators. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.Lancet. 2010; 376(9742): 687-697.
20 Li J, Qin S, Xu J, Guo W, Xiong J, Bai Y, Sun G, Yang Y, Wang L, Xu N, Cheng Y, Wang Z, Zheng L, Tao M, Zhu X, Ji D, Liu X, Yu H.Apatinib for chemotherapyrefractory advanced metastatic gastric cancer: results from a randomized, placebo-controlled, parallel-arm, phase II trial.J Clin Oncol. 2013; 31(26): 3219-3225.
21 Sun W, Powell M, O’Dwyer PJ, Catalano P, Ansari RH, Benson AB 3rd. Phase II study of sorafenib in combination with docetaxel and cisplatin in the treatment of metastatic or advanced gastric and gastroesophageal junction adenocarcinoma: ECOG 5203.J Clin Oncol. 2010; 28(18): 2947-2951.
22 Zhao Y, Wang XW, Lu Y, Liu X, Xiu LJ, Yue XQ, Wei PK. Effect of Xiaotan Sanjie decoction treatment based on syndrome differentiation on quality of life of patients with intermediate and advanced gastric cancer. Di Er Jun Yi Da Xue Xue Bao.2016; 37(11): 1333-1337. Chinese with abstract in English.
23 Zhao AG, Cao W, Xu Y, Zhao G, Liu BY, Yang JZ, Gu Y, Yuan W, Zhu YJ, Han YY, Yang JK. Survival benefit of an herbal formula for invigorating spleen for elderly patients with gastric cancer. Zhong Xi Yi Jie He Xue Bao.2010; 8(3): 224-230. Chinese with abstract in English.
24 Sun DZ, Jiao JP, Ju DW, Ye M, Zhang X, Xu JY, Lu Y, He J, Wei PK, Yang MH.Tumor interstitial fluid and gastric cancer metastasis: an experimental study to verify the hypothesis of “tumor-phlegm microenvironment”.Chin J Integr Med. 2012; 18(5): 350-358.
25 Shi J, Wei PK.Xiaotan Sanjie decoction inhibits interleukin- 8-induced metastatic potency in gastric cancer. World J Gastroenterol.2015; 21(5): 1479-1487.
26 Yan B, Liu L, Zhao Y, Xiu LJ, Sun DZ, Liu X, Lu Y, Shi J, Zhang YC, Li YJ, Wang XW, Zhou YQ, Feng SH, Lv C, Wei PK, Qin ZF.Xiaotan Sanjie decoction attenuates tumor angiogenesis by manipulating Notch-1-regulated proliferation of gastric cancer stem-like cells.World J Gastroenterol. 2014; 20(36): 13105-13118.
27 Yan B, Zhou Y, Feng S, Lv C, Xiu L, Zhang Y, Shi J, Li Y, Wei P, Qin Z.β-Elemene-attenuated tumor angiogenesis by targeting Notch-1 in gastric cancer stem-like cells.Evid Based Complement Alternat Med. 2013; 2013: 268468.
28 Ju D, Sun D, Xiu L, Meng X, Zhang C, Wei P.Interleukin-8 is associated with adhesion, migration and invasion in human gastric cancer SCG-7901 cells.Med Oncol. 2012; 29(1): 91-99.
[1] Tara Rajendran. Addressing the need for personalizing music therapy in integrative oncology. Journal of Integrative Medicine, 2022, 20(4): 281-283.
[2] Rui-jin Qiu, Min Li, Jia-yuan Hu, Jing Chen, Hong-cai Shang. Methods for development of a core outcome set for clinical trials integrating traditional Chinese medicine and Western medicine. Journal of Integrative Medicine, 2021, 19(5): 389-394.
[3] Sibel Şentürk, Dilek Efe Arslan, Adil Çetinkaya. Association of complementary and integrative therapy use and symptoms among Turkish patients with familial Mediterranean fever. Journal of Integrative Medicine, 2021, 19(4): 340-346.
[4] Baoyi Shao, Saiying Hou, Yuenyan Chan, Changchun Shao, Lixing Lao. Remission of new-onset type 2 diabetes mellitus in an adolescent using an integrative medicine approach: A case report. Journal of Integrative Medicine, 2021, 19(1): 85-88.
[5] George Chengxi Bao. The idealist and pragmatist view of qi in tai chi and qigong: A narrative commentary and review. Journal of Integrative Medicine, 2020, 18(5): 363-368.
[6] Brody Slostad, Tejinder Khalsa, Kathleen Young, Hildalicia Guerra, Anjali Bhagra. A case-based approach to integrative medicine for cardiovascular disease prevention. Journal of Integrative Medicine, 2020, 18(2): 159-162.
[7] Mikhail Teppone. Medicine has always been “Modern” and “Scientific” from ancient times to the present day. Journal of Integrative Medicine, 2019, 17(4): 229-237.
[8] Mohammad Hossein Ayati, Ata Pourabbasi, Nazli Namazi, Arman Zargaran, Zahra Kheiry, Amir Hooman Kazemi, Bagher Larijani. The necessity for integrating traditional, complementary, and alternative medicine into medical education curricula in Iran. Journal of Integrative Medicine, 2019, 17(4): 296-301.
[9] Tamer Aboushanab, Mohamed Khalil, YaserAl Ahmari. The present state of complementary medicine regulation in Saudi Arabia. Journal of Integrative Medicine, 2019, 17(3): 147-149.
[10] Hanae Naceiri Mrabti, Nidal Jaradat, Mohamed Reda Kachmar, Abdelaziz Ed-Dra, Abdelilah Ouahbi, Yahia Cherrah, Moulay El Abbes Faouzi. Integrative herbal treatments of diabetes in Beni Mellal region of Morocco. Journal of Integrative Medicine, 2019, 17(2): 93-99.
[11] Fung-Kei Cheng. An overview of the contribution of acupuncture to thyroid disorders. Journal of Integrative Medicine, 2018, 16(6): 375-383.
[12] Chang-quan Ling, Jia Fan, Hong-sheng Lin, Feng Shen, Zhen-ye Xu, Li-zhu Lin, Shu-kui Qin, Wei-ping Zhou, Xiao-feng Zhai, Bai Li, Qing-hui Zhou, on behalf of the Chinese Integrative Therapy of Primary Liver Cancer Working Group. Clinical practice guidelines for the treatment of primary liver cancer with integrative traditional Chinese and Western medicine. Journal of Integrative Medicine, 2018, 16(4): 236-248.
[13] Nian Huang. Integrative medicine is an evolving field and the future of healthcare: A summary of the 2017 Integrative Medicine Shanghai Forum. Journal of Integrative Medicine, 2018, 16(2): 71-71.
[14] Saswati Mahapatra, Anjali Bhagra, Bisrat Fekadu, Zhuo Li, Brent A. Bauer, Dietlind L. Wahner-Roedler. Incorporation of integrative medicine education into undergraduate medical education: A longitudinal study. Journal of Integrative Medicine, 2017, 15(6): 442-449.
[15] Andrian Liem, Kuncoro Dewi Rahmawati. The meaning of complementary, alternative and traditional medicine among the Indonesian psychology community: A pilot study. Journal of Integrative Medicine, 2017, 15(4): 288-294.
Full text



[1] Dong Yang, Yong-ping Du, Qing Shen, Wei Chen, Yan Yu, Guang-lei Chen. Expression of alpha-smooth muscle actin in renal tubulointerstitium in patients with kidney collateral stasis. Journal of Chinese Integrative Medicine, 2008, 6(1): 41-44
[2] Hai-feng Wei, Bai-liu Ya, Ling Zhao, Cui-fei Ye, Li Zhang, Lin Li. Evaluation of tongue manifestation of blood stasis syndrome and its relationship with blood rheological disorder in a rat model of transient brain ischemia. Journal of Chinese Integrative Medicine, 2008, 6(1): 73-76
[3] Xi Lin, Jian-ping Liu. Herbal medicines for viral myocarditis. Journal of Chinese Integrative Medicine, 2008, 6(1): 76
[4] Xi Lin, Jian-ping Liu. Tai chi for treating rheumatoid arthritis. Journal of Chinese Integrative Medicine, 2008, 6(1): 82
[5] Liang-ping Hu, Hui Gao. Discrimination of errors in statistical analysis of medical papers published in the first issue of 2006 in Journal of Chinese Integrative Medicine. Journal of Chinese Integrative Medicine, 2008, 6(1): 98-106
[6] Yan-bo Zhu , Qi Wang, Cheng-yu Wu, Guo-ming Pang, Jian-xiong Zhao, Shi-lin Shen, Zhong-yuan Xia , Xue Yan . Logistic regression analysis on relationships between traditional Chinese medicine constitutional types and overweight or obesity. Journal of Chinese Integrative Medicine, 2010, 8(11): 1023-1035
[7] Wei Xu, Meng Shi, Jian-gang Liu, Cheng-long Wang . Collagen protein expressions in ischemic myocardium of rats with acute myocardial infarction and effects of qi-tonifying, yin-tonifying and blood-activating herbs and detoxifying and blood-activating herbs. Journal of Chinese Integrative Medicine, 2010, 8(11): 1041-1047
[8] Tao Wang , Feng Qin. Effects of Chinese herbal medicine Xiaoyao Powder on monoamine neurotransmitters in hippocampus of rats with postpartum depression. Journal of Chinese Integrative Medicine, 2010, 8(11): 1075-1079
[9] Ying Xu , Chang-chun Zeng , Xiu-yu Cai , Rong-ping Guo , Guang Nie , Ying Jin. Chromaticity and optical spectrum colorimetry of the tongue color in different syndromes of primary hepatic carcinoma. Journal of Chinese Integrative Medicine, 2012, 10(11): 1263-1271
[10] Xiang-ying Mao , Qin Bian , Zi-yin Shen. Analysis of the osteogenetic effects exerted on mesenchymal stem cell strain C3H10T1/2 by icariin via MAPK signaling pathway in vitro. Journal of Chinese Integrative Medicine, 2012, 10(11): 1272-1278